All‐cause mortality · adults undergoing cardiac surgery with cardiopulmonary bypass
It is very uncertain whether high changes all‐cause mortality compared with low blood pressure target (very low certainty).
1 finding from 1 review
All‐cause mortality · people undergoing bariatric surgery
1 finding from 1 review
All‐cause mortality · people undergoing bariatric surgery
1 finding from 1 review
All‐cause mortality · people undergoing bariatric surgery
1 finding from 1 review
All‐cause mortality · people undergoing bariatric surgery
1 finding from 1 review
All‐cause mortality · adults after heart valve surgery
It is very uncertain whether exercise changes all‐cause mortality compared with no exercise (very low certainty).
1 finding from 1 review
All‐cause mortality · patients undergoing surgery for head and neck cancer
Immunonutrition showed no clear difference in all‐cause mortality compared with standard care (low certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality · individuals with atrial fibrillation who are undergoing cardiac surgery
The intervention showed no clear difference in all‐cause mortality (low certainty).
1 finding from 1 review
All‐cause mortality · participants with improving outcomes during and after noncardiac vascular surgery.
Perioperative statins showed no clear difference in all‐cause mortality compared with placebo or no treatment (low certainty).
1 finding from 1 review
Mortality within the longest · Children having heart surgery with cardiopulmonary bypass
Glucocorticoid showed no clear difference in all‐cause mortality at longest compared with placebo (moderate certainty).
1 finding from 1 review
Mortality within the longest · adults undergoing non‐cardiac surgery
Continuation showed no clear difference in all‐cause mortality (at longest compared with discontinuation of antiplatelet therapy (low certainty).
1 finding from 1 review
All‐cause mortality up to 30 days · people aged 18 and over undergoing vascular surgery
1 finding from 1 review
All‐cause mortality up to 30 days · people aged 18 and over undergoing vascular surgery
It is very uncertain whether summary of findings: Fibrin sealant changes all‐cause mortality up to 30 days compared with usual care (very low certainty).
1 finding from 1 review
Mortality within the longest · adult surgical patients with the need for cardiopulmonary bypass‐dependent heart surgery
It is very uncertain whether pulmonary artery perfusion with blood changes all‐cause mortality within longest compared with no perfusion during cardiopulmonary bypass (very low certainty).
1 finding from 1 review
Mortality within the longest · adults receiving intravenous fluids while undergoing major non‐cardiac surgery
It is very uncertain whether perioperative restrictive fluid therapy changes all‐cause mortality (during longest compared with goal‐directed fluid therapy (very low certainty).
1 finding from 1 review
All‐cause mortality rate at 30 days · adults having abdominal surgery
Epidural analgesia showed no clear difference in all‐cause mortality rate at 30 days compared with intravenous patient‐controlled analgesia (low certainty).
1 finding from 1 review
All‐cause mortality (up to 30 days) · adults undergoing non‐cardiac surgery
Continuation showed no clear difference in all‐cause mortality (up to 30 days) compared with discontinuation of antiplatelet therapy (low certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality (within 30 days) · adults undergoing cardiac surgery under general anaesthesia
The intervention showed no clear difference in all‐cause mortality (within 30 days) (low certainty).
1 finding from 1 review
All‐cause mortality · people with liver metastases
1 finding from 1 review
Neonatal mortality · neonates born from 35 weeks of gestation who have underdone gastrointestinal surgery
1 finding from 1 review